Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amphiphilic nanoparticles repress macrophage atherogenesis: novel core/shell designs for scavenger receptor targeting and down-regulation.

Molecular pharmaceutics - 4 Aug 2014

Petersen Latrisha K, York Adam W, Lewis Daniel R, Ahuja Sonali, Uhrich Kathryn E, Prud'homme Robert K, Moghe Prabhas V

Abstract excerpt

Atherosclerosis, an inflammatory lipid-rich plaque disease is perpetuated by the unregulated scavenger-receptor-mediated uptake of oxidized lipoproteins (oxLDL) in macrophages. Current treatments lack the ability to directly inhibit oxLDL accumulation and foam cell conversion within diseased arte...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arteriosclerosis
Share to CD36 Antigens
Share to Foam Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipoproteins, LDL

Share to Nanoparticles

Share to Nanotechnology

Share to Plaque, Atherosclerotic

Share to Scavenger Receptors, Class A

Source

Open in PubMed Open full text

Identifiers

PMID: 24972372
DOI: 10.1021/mp500188g
PMCID: PMC4144725

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24972372-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amphiphilic nanoparticles repress macrophage atherogenesis: novel core/shell designs for scavenger receptor targeting and down-regulation.PMID 24972372Read ↗

Biomimetic Nanoparticles Simultaneously Targeting Modulation of Lipid Metabolism and Phenotype of Macrophages for Programmed Atherosclerosis Management.Semantic proximity Read ↗

Nrf2 activator-encapsulating polymeric nanoparticles and LDL-like nanoparticles target atherosclerotic plaqueSemantic proximity Read ↗

The Role of Macrophages in Atherosclerosis: Pathophysiologic Mechanisms and Treatment Considerations.Semantic proximity Read ↗

Metabolic-switch macrophage cyborgs reverse atherosclerosis by photoacoustic-directed on-demand phenotype delivery.Semantic proximity Read ↗

Structure-activity relations of nanolipoblockers with the atherogenic domain of human macrophage scavenger receptor A.Semantic proximity Read ↗

Targeted delivery of RNA-based therapeutics enables functional analysis of macrophage subpopulationsSemantic proximity Read ↗

Lesion-specific suppression of YAP/TAZ by biomimetic nanodrug ameliorates atherosclerosis developmentSemantic proximity Read ↗

Antioxidant Response Activating nanoParticles (ARAPas) localize to atherosclerotic plaque and locally activate the Nrf2 pathwaySemantic proximity Read ↗

A drug-free, engineered hybrid exosome platform alleviates atherosclerosis via inflammation modulation and phenotype remodeling.Semantic proximity Read ↗

Precise theranostic nanomedicines for inhibiting vulnerable atherosclerotic plaque progression through regulation of vascular smooth muscle cell phenotype switching.Semantic proximity Read ↗

Apoptotic body-inspired nanoparticles target macrophages at sites of inflammation to support an anti-inflammatory phenotype shift.Semantic proximity Read ↗

A PEG-PLGA-based polymeric capsule as theranostic nanoplatform for active targeting atherosclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.